Kymera Therapeutics (NASDAQ:KYMR) Given New $125.00 Price Target at JPMorgan Chase & Co.

Kymera Therapeutics (NASDAQ:KYMR) had its target price upped by JPMorgan Chase & Co. from $70.00 to $125.00 in a research report report published on Wednesday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other equities analysts have also commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Truist Financial increased their target price on Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a research report on Tuesday. Guggenheim began coverage on Kymera Therapeutics in a report on Monday, November 3rd. They issued a “buy” rating and a $90.00 target price on the stock. Finally, Stifel Nicolaus set a $114.00 price target on Kymera Therapeutics in a research note on Monday. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $108.35.

Kymera Therapeutics Trading Up 3.5%

Shares of NASDAQ:KYMR opened at $89.89 on Wednesday. The firm has a market cap of $6.47 billion, a price-to-earnings ratio of -25.04 and a beta of 2.28. The stock’s 50-day moving average price is $63.50 and its two-hundred day moving average price is $51.18. Kymera Therapeutics has a 12-month low of $19.44 and a 12-month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The company had revenue of $2.76 million for the quarter, compared to analyst estimates of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. As a group, research analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Jared Gollob sold 59,576 shares of the company’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $61.42, for a total value of $3,659,157.92. Following the completion of the sale, the insider owned 109,992 shares of the company’s stock, valued at $6,755,708.64. This represents a 35.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Nello Mainolfi sold 100,000 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $89.17, for a total value of $8,917,000.00. Following the completion of the sale, the chief executive officer owned 660,482 shares of the company’s stock, valued at approximately $58,895,179.94. This trade represents a 13.15% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 361,217 shares of company stock worth $25,140,500. Company insiders own 16.01% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Several large investors have recently bought and sold shares of KYMR. Wellington Management Group LLP lifted its position in shares of Kymera Therapeutics by 13.0% during the first quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company’s stock worth $164,134,000 after purchasing an additional 689,547 shares in the last quarter. BVF Inc. IL grew its holdings in Kymera Therapeutics by 6.6% during the 2nd quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock valued at $240,138,000 after purchasing an additional 340,909 shares in the last quarter. Vanguard Group Inc. increased its stake in Kymera Therapeutics by 7.0% during the 1st quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock worth $143,183,000 after buying an additional 344,080 shares during the period. Siren L.L.C. lifted its holdings in Kymera Therapeutics by 9.1% in the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company’s stock worth $88,687,000 after buying an additional 270,580 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Kymera Therapeutics by 5.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock worth $52,075,000 after buying an additional 59,347 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.